Hydrocortisone
DrugHydrocortisone administered for the treatment of adrenal insufficiency in participants with severe sepsis.
NCT Number: NCT00368381
The purpose of this study is to determine if the combination of hydrocortisone plus fludrocortisone is more efficacious than hydrocortisone alone in treating adrenal insufficiency in severe sepsis.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Sepsis is a significant cause of morbidity and mortality in critically ill patients in the United States. As evidenced by its increasing prevalence and high mortality rates, sepsis is a complex and difficult syndrome to treat. Current therapeutic management of sepsis includes fluid resuscitation, vasopressor and inotropic support, maintenance of oxygen delivery, drotrecogin alpha, and steroid replacement therapy in patients who are found to have adrenal insufficiency. Studies in septic patients suggest that the administration of stress doses of hydrocortisone alone, or the combination of hydrocortisone plus fludrocortisone promotes an improvement in cardiovascular performance and a quicker resolution of shock symptoms. Current therapeutic guidelines for the treatment of severe sepsis recommend either hydrocortisone alone or combination therapy with hydrocortisone and fludrocortisone as therapeutic options for the treatment of adrenal dysfunction in severe sepsis. This study will help determine which regimen is more efficacious in this patient population.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patient satisfies criteria for severe sepsis Infection - one or more of the following criteria
SIRS - two or more of the following
Acute organ dysfunction - one or more of the following
Exclusion criteria
Hydrocortisone administered for the treatment of adrenal insufficiency in participants with severe sepsis.
Fludrocortisone administered in combination with hydrocortisone for the treatment of adrenal insufficiency in participants with severe sepsis.
Time frame: 28 days
All cause mortality during first 28-days after study randomization.
Time frame: Unable to define
The various secondary endpoints are patient specific serrogate markers of improvement in clinical status. Time frame for these endpoints to occur is patient specific and can not be defined for the entire study population.
CAMC Health System
Other
A Blinded, Placebo Controlled Trial of Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01904188
Antibiotic Resistance Genes, Bacterial Infections
Lansing, Michigan, United States
View Trial DetailsNCT04203979
Infections, Inflammation
Oslo, Norway
View Trial DetailsNCT07460024
Critical Illness, Disease Attributes
View Trial DetailsNCT06446947
Infections, Inflammation
Marseille, Bouches du Rhône, France
View Trial Details